

Major shareholder announcement

Pursuant to Section 30 of the Danish Capital Markets Act, Novonesis hereby announces that Novo Nordisk Fonden has on its own behalf and on behalf of its wholly owned subsidiary Novo Holdings A/S notified Novonesis, that as of yesterday, Novo Nordisk Fonden and Novo Holdings A/S, indirectly and directly, respectively, holds a total of 53,743,600 A-shares (nominally DKK 107,487,200) and 65,672,555 B-shares (nominally DKK 131,345,110) corresponding to 25.50% of the entire issued share capital and 63.35% of the total voting rights in Novozymes A/S, part of Novonesis Group.

June 21, 2024

Company announcement No. 22

Contact information

Tobias Bjorklund
+45 3077 8682
tobb@novonesis.com

Anders Enevoldsen
+45 5350 1453
adev@novonesis.com

Disa Tuominen
+45 6038 5826
ditu@novonesis.com

About Novonesis

Novonesis is a global leading biosolutions company transforming the way we all produce, consume and live. In more than 30 industries our biosolutions are helping companies meet their business needs and the needs of our planet. Our 10,000 people worldwide work closely with our partners and customers to challenge conventional thinking and transform business with biology.

Novozymes A/S, part of Novonesis Group

Krogshøjvej 36
2880 Bagsvaerd
Denmark